Evidence map›Paper›PMID 39920126›Full record

ArticleTranslational psychiatry2025

Methods to address functional unblinding of raters in CNS trials.

Steven D Targum, William P Horan, Vicki G Davis, Alan Breier, Stephen K Brannan

Abstract read
In one paragraph

Article in Translational psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Steven D Targum, Boston, MA, USA. sdtargum@yahoo.com.ORCID http://orcid.org/0000-0003-1054-5197
William P HoranBristol Myers Squibb, Princeton, NJ, USA.
Vicki G DavisStatistical Consultant, Chapel Hill, NC, USA.
Alan BreierDepartment of Psychiatry, Indiana University School of Medicine, Indianapolis, IN, USA.
Stephen K BrannanBristol Myers Squibb, Princeton, NJ, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Treatment-emergent adverse events (TEAEs) associated with the unique properties of a pharmaceutical product may functionally unblind clinician ratings, obscure true medication effects, and affect confidence about clinical trial results. Central nervous system studies are particularly susceptible to functional unblinding because they rely on relatively subjective symptom assessments. Two different methods were used to examine possible functional unblinding in pooled data from three recent five-week, double-blind, placebo-controlled trials of xanomeline and trospium chloride (formerly known as KarXT) in participants with schizophrenia experiencing acute psychosis. Xanomeline/trospium is an M

Indexed as

Antipsychotic AgentsBenzilatesMuscarinic AgonistsPsychotic DisordersSchizophreniaAdultDouble-Blind MethodFemaleHumansMaleMiddle AgedPsychiatric Status Rating ScalesPyridinesThiadiazolesAntipsychotic AgentsBenzilatesMuscarinic AgonistsPyridinesThiadiazolesxanomeline

Identifiers

PMID39920126
PMCPMC11805955

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.